Boro Dropulić, Vector BioMed CEO

Vec­tor Bio­Med launch­es with $15M to pro­duce back­logged CAR-T com­po­nent

The man­u­fac­ture of lentivi­ral vec­tors has been grab­bing the at­ten­tion of in­vestors both small and large as of late, and an­oth­er man­u­fac­tur­er is look­ing to jump on­to the scene.

Vec­tor Bio­Med, a Mary­land-based bio­man­u­fac­tur­ing com­pa­ny, has raised $15 mil­lion, ac­cord­ing to CEO Boro Drop­ulić in an in­ter­view with End­points News. The im­pe­tus be­hind the com­pa­ny, Drop­ulić said, is for Vec­tor Bio­Med to fill a gap in the de­mand and ac­cess to lentivi­ral vec­tors, a key com­po­nent in CAR-T ther­a­pies and oth­er treat­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.